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Abstract
Background: The conduct of oral food challenges as the preferred diagnostic stan-
dard for food allergy (FA) was harmonized over the last years. However, docu-
mentation and interpretation of challenge results, particularly in research settings,
are not sufficiently standardized to allow valid comparisons between studies. Our
aim was to develop a diagnostic toolbox to capture and report clinical observa-
tions in double-blind placebo-controlled food challenges (DBPCFC).
Methods: A group of experienced allergists, paediatricians, dieticians, epidemiolo-
gists and data managers developed generic case report forms and standard oper-
ating procedures for DBPCFCs and piloted them in three clinical centres. The
follow-up of the EuroPrevall/iFAAM birth cohort and other iFAAM work pack-
ages applied these methods.
Recommendations: A set of newly developed questionnaire or interview items cap-
ture the history of FA. Together with sensitization status, this forms the basis for
the decision to perform a DBPCFC, following a standardized decision algorithm.
A generic form including details about severity and timing captures signs and
symptoms observed during or after the procedures. In contrast to the commonly
used dichotomous outcome FA vs no FA, the allergy status is interpreted in mul-
tiple categories to reflect the complexity of clinical decision-making.
Conclusion: The proposed toolbox sets a standard for improved documentation
and harmonized interpretation of DBPCFCs. By a detailed documentation and
Abbreviations
CRF, case report form; DBPCFC, double-blind, placebo-controlled food challenge; FA, food allergy; iFAAM, integrated approaches to food
allergen and allergy risk management; IgE, immunoglobulin E; SOP, standard operating procedure; SPT, skin prick test.
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Allergy
common terminology for communicating outcomes, these tools hope to reduce
the influence of subjective judgment of supervising physicians. All forms are pub-
licly available for further evolution and free use in clinical and research settings.
In the clinical setting, diagnosing food allergy (FA) requires a
comprehensive workup, including a detailed history, individu-
alized decisions for assessing sensitization and, if warranted,
oral food challenges guided by recently developed standards
(1–6). However, there is no established methodology for sys-
tematically assessing FA in research settings, which would
require a priori defined approaches suitable for entire study
populations. The multinational EuroPrevall birth cohort study
pioneered a systematic framework to estimate the frequency
and patterns of FA in European children (7, 8). It has been
recognized that thorough oral food challenges are required to
confirm suspected allergic reactions to food in observational
and intervention studies, preferably as double-blind placebo-
controlled food challenges (DBPCFC). Supervised open food
challenges (no placebo test, no blinding) are considered suffi-
cient to prove tolerance to a specific food item (9). A group of
clinical FA researchers suggested guidelines for a standardized
assessment of DBPCFCs in such research settings (PRAC-
TALL) (1). Although oral food challenge tests in clinical set-
tings have been increasingly harmonized, their results are not
always clear-cut and their interpretation is still challenging,
particularly for comparative systematic evaluations (10–13).
Our aim was to develop a diagnostic toolbox to identify
individuals with possible FA who should undergo a
DBPCFC for use in population-based and clinical studies
and to make recommendations for a stringent documentation
and interpretation of food challenge results.
Methods
The interobserver differences experienced in the EuroPrevall
birth cohort’s highly standardized food challenges prompted
our development of a new toolbox of refined methods for
diagnosing FA. The follow-up assessment of the EuroPrevall
birth cohort as part of the pan-European iFAAM project
(EU grant agreement number 312147) already applied these
methods. They were developed as generic blueprints, applica-
ble in observational and interventional research, and routine
care. The case report forms (CRFs) and standard operating
procedures (SOPs) are publicly and freely available. Paedia-
tricians, dieticians, epidemiologists and data managers with
extensive experience in translational research and clinical
practice led the development of these tools, based on the pre-
viously published guideline of the PRACTALL group (1).
Three specialist clinics (Southampton and Manchester, UK;
Berlin, Germany) piloted all CRFs and SOPs.
Recommendations
Questionnaire assessment of earlier FA history
We propose a number of new questions for the assessment of
prior reactions to foods. These questions are phrased for
parent- or self-reported reactions. To allow the calculation of
comparable frequency estimates in research settings, a list of
commonly observed allergenic foods should be presented.
Further (country- and culture-specific) suspected food aller-
gens can be added and should be reported as free text. Three
different diagnostic levels are distinguished as follows: par-
ent-/self-reported reactions to food (‘Have you/Has your
child ever had an illness or trouble caused by eating a food
or foods and/or a diagnosis of food allergy?’ Yes/No), par-
ent-/self-reported doctor’s diagnosis of FA (‘Have you/Has
your child ever been diagnosed by a doctor as having an
allergy to this food?’ Yes/No) and parent-/self-reported chal-
lenge-proven FA (‘if yes, was this diagnosis supported by a
food challenge in a clinic or practice?’ Yes/No or don’t
know).
Age (in years, optional: in months, for the first one/two
years) at first symptoms/diagnosis (‘How old were you/was
your child when these symptoms first occurred?’) and when
the patient was eating the food again without symptoms (‘I/
The child was able to eat the food without symptoms begin-
ning at the age of:’) or when the patient last ate the food
with subsequent symptoms (‘I/The child had symptoms the
last time I/he/she ate the food at the age of:’) can be used as
indicators of onset, disease duration and tolerance develop-
ment. Furthermore, parent-/self-reported symptoms (e.g. itch-
ing, rash, diarrhoea) and the interval between exposure and
symptoms should be recorded (‘How soon after eating did
the symptoms occur?’ Within 2 h/After 2 h/Both).
Medical history and sensitization status
Current FA status of a patient can be evaluated clinically
after a face-to-face or telephone interview assessing the FA
history, including recent symptoms and consumption (last
3 months) of core foods. The list of core foods should be
defined while planning a study and may include typical, fre-
quent and/or clinically relevant food-allergen sources. For
the multitude of foods not on this list, the consumption his-
tory is only recorded in case of earlier problems. This means
there is no information on the number of people who ate the
food recently, thus tolerating it. Without a robust estimate
for the number of tolerant individuals, valid estimates of
disease frequency cannot be calculated. These foods can
therefore only be evaluated and reported on a descriptive
case-by-case basis.
At first, a skin prick test (SPT) (14), or specific
immunoglobulin E (IgE) testing for all a priori defined core
foods, additionally relevant foods and potential sources of
cross-reacting aeroallergens (e.g. grass pollen, birch pollen)
should be performed to determine sensitization. The reagents
used for SPTs in a research project should be described in
detail (e.g. fresh foods, commercial extracts, the latter were
used in the EuroPrevall/iFAAM birth cohort). Similarly, the
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method for measuring allergen-specific IgE should be speci-
fied. The physician’s appraisal of whether the patient is aller-
gic to the foods in question, just based on the interview/
conversation, can be used as an additional study end point
(‘Do you, as the physician, think that the reported history is
suggestive of prior and/or current food allergy/hypersensitiv-
ity?’ (1) Yes, very likely (2) Possibly (I would evaluate
further) (3) Possibly (but I would NOT evaluate further) (4)
No, unlikely). This question is explained further by the fol-
lowing examples: (1) plausible history of repeated reactions
or prior anaphylaxis (2) single reaction followed by avoid-
ance or symptoms not always associated with food (3) vague
history or no plausible link to ingestion (4) never experienced
a reaction or the history is incompatible with food hypersen-
sitivity. This item can serve as a proxy outcome for those eli-
gible but refusing challenge testing.
Eligibility for oral food challenge
The decision whether suspected FA is confirmed or ruled out
through a DBPCFC should be based on information from
the interview/questionnaire assessment and the allergic sensi-
tization status (e.g. SPT wheal diameter ≥3 mm or specific
IgE levels ≥0.35 kU/l), following the outlined decision algo-
rithm (decision tree, Fig. 1).
Food allergy is very unlikely, and a person does not need
to undergo an oral food challenge if they have either eaten
the food recently (in the last 3 months) without symptoms
(eligibility type A), or have not eaten it recently but never
had symptoms and are not sensitized (type B, Table 1).
In research, there are two indications for an oral food
challenge: if a person is sensitized and if a food in question
has not been eaten in the last 3 months without symptoms or
the food was never consumed at all. This is necessary to
screen yet unnoticed FA allowing estimation of FA preva-
lence (type C). If a person has had symptoms after eating a
specific food at any time in their life and has either never tol-
erated it again or has tolerated it at some point but has not
consumed it recently without symptoms, then a DBPCFC
should be conducted to establish the current status of FA,
regardless of the allergic sensitization status (type D,
Table 1). There may be contraindications like a plausible
report of recent anaphylaxis.
In all research settings, the type of eligibility (A–D) should
be recorded for each food in question to allow better
interpretation and comparability between study physicians,
centres and studies.
Oral food challenge conduct and documentation
To reduce the overall number of challenge days and thus
increase compliance, foods are grouped based on a com-
mon matrix used for blinding, herein called challenge
blocks. For example, cow’s milk and hen’s egg powder can
be blinded in the same matrix and thus be assessed on sep-
arate days within a single challenge block. For each of
these blocks, only one placebo day needs to be scheduled
and used as the reference for up to the maximum number
of verum days (e.g. three), instead of one placebo day for
each verum day.
To ensure also blinding of the staff attending the proce-
dure, the dietician preparing the challenge meal shuffles the
order of food allergens and placebo within a challenge block
randomly, for example using a randomization list. The
assignment of food allergens/placebo to actual challenge days
is kept secret until finishing the whole challenge block, unless
emergency unblinding is required.
All observations made on a challenge day can be docu-
mented in the challenge day form (Fig. 2). The DBPCFC
schedules are typically comprised of 7–9 escalating doses,
usually in intervals of 20–30 min. Signs and symptoms
should be recorded in relation to the last dose consumed,
specifying the exact time at onset of skin, respiratory, gas-
trointestinal, neurological or cardiovascular symptoms. The
attending physician is asked to report symptom severity
based on suggestions by the PRACTALL consensus report
(1). For example, number of hives, number of episodes of
vomiting and diarrhoea, impact and duration of scratching,
or the area affected by rash are recorded.
Symptoms within the last 24 h before the challenge day
are recorded to differentiate between newly occurring and
pre-existing or recurrent symptoms. Objective parameters
(blood pressure, pulmonary function) can be assessed and
documented if considered necessary, for example based on
prior reactions or safety concerns. The challenge is stopped
upon predetermined criteria such as vomiting or urticaria
(highlighted as orange and red symptoms in the form,
Fig. 2). However, the final decision to stop the procedure is
always at the discretion of the attending physician. After a
stopped challenge or reaching the final dose as scheduled, the
patient remains under clinical observation for at least 2 h.
Symptoms occurring up to 24 h after the last dose can be
recorded as an indicator of a delayed reaction. Therefore,
final appraisal of the challenge day is deferred until then. An
SOP for using the documentation form (Fig. 2) is available
online (open access online supplement, updated versions and
other languages at www.diagnosing-food-allergy.org).
Each DBPCFC day (placebo and verum separately) is rated
negative if all planned doses were given with no clinical signs/
symptoms or if observed signs/symptoms are not thought to
be caused by the test food. It is rated positive if (objective)
clinical signs or symptoms in relation to the tested food item
occur – as proposed by Vlieg-Boerstra and later adapted by
Sampson (1, 15). In addition to these two categories, we sug-
gest to define a challenge day as inconclusive if the reported
signs/symptoms are not clearly attributable to the assessed
food item (e.g. if similar signs/symptoms were reported ear-
lier) or if a challenge day was stopped before reaching the
final dose without ingestion-related signs/symptoms.
Additionally, study physicians document their reasons
leading to the final conclusion. The form requires the clini-
cian to subjectively appraise the severity of the reactions on a
scale from 0 to 10: firstly, based on just the signs and symp-
toms; secondly, including the length of exposure-reaction
intervals, necessity of medical interventions and other infor-
mation from the medical history or observation of the
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procedure; and thirdly, from the patient’s (or parent’s) per-
spective. This information allows assessing potential hetero-
geneity in DBPCFC outcome decisions between individual
study physicians in a single centre and between study centres
in multicentre studies.
Negative food challenges should be confirmed by serving
the cumulative full dose of allergen in a single meal on one
of the following days (16).
Defining food allergy
Food allergy is usually handled as a dichotomous state:
either food allergic or food tolerant (15). In clinical practice,
physicians see a whole spectrum of reactions, from distress,
self-reported symptoms to mild or stronger objective clinical
signs, and up to potentially fatal reactions. Splitting this orig-
inally continuous (and multidimensional) outcome into a
dichotomous decision of being allergic or tolerant is often
necessary to give dietary advice. However, it not only dis-
cards valuable information but also requires a clear cutoff
that is agreed-on and applied by different physicians to be
useful in (comparative) research.
Recording graded signs and symptoms and semi-quantita-
tive perceived severity allows modelling of challenge day out-
comes in a continuous fashion. Now, when judging the
overall status in the light of both a placebo and a verum
challenge, physicians should be asked to classify FA status
within 10 meaningful levels, separating three broad outcome
categories: ‘NO food allergy’, ‘UNCERTAIN outcome’ and
‘FOOD ALLERGY’ (Fig. 3). This allows comparison of
detailed outcome information and adjustment for systematic
differences such as proportion of placebo reactors as an indi-
cator of individual cutoffs for interpreting challenge symp-
toms. We encourage researchers and clinicians alike to use a
similar terminology for DBPCFC outcome assessments, sup-
porting combined data analyses across studies and allergy
clinics. In clinical care, an UNCERTAIN outcome is not
helpful for the patient and further diagnostic evaluation and
follow-up care may be needed.
Discussion
We developed a framework for a harmonized diagnosis of
food allergies in population-based and clinical research as
part of the EU-funded iFAAM project, based on experiences
from the EuroPrevall project, and previously developed stan-
dards (1, 15). The follow-up of the iFAAM/EuroPrevall birth
cohort applied our protocol and decision algorithm. This
diagnostic toolbox pioneers a generic questionnaire and inter-
view items specifically on previous and current food allergies,
in addition to the widely used set of allergy-related questions
in interviews and questionnaires (17).
Based on a physician-administered interview and allergic
sensitization tests, we developed a decision algorithm for eli-
gibility to undergo DBPCFC tests, standardizing the triage
for further diagnosis. Thorough documentation of the type
of eligibility supports the extrapolation of frequency esti-
mates for food allergies in the population. This will also
allow taking account of challenge testing that is offered but
declined or avoided. For example, one can use the propor-
tion of positive DBPCFCs in individuals who became eligible
when not eating a food and being sensitized, to estimate the
number of undetected allergic individuals of those with the
same eligibility criteria refusing challenge testing. The PRAC-
TALL group stressed the need to grade signs and symptoms
of food allergic reactions (1). Based on their consensus report
and our evaluations of the multinational EuroPrevall birth
cohort study up to age 2 (18–20), we developed and piloted a
generic one-page form for the documentation of a complete
food challenge day. This form will not only allow a grading
of clinical signs and subjective symptoms, but also a specifi-
cation of the exact time when signs and symptoms started,
and will give an indication of subjective severity assessments
of the reactions. If used in future projects, comparison
between centres, studies and populations on the lowest sign-
and symptom-based level for a positive reaction will be possi-
ble. Furthermore, graded symptoms, subjective severity scor-
ing and multilevel DBPCFC outcomes will improve
comparability of physician-specific sign/symptom cutoffs,
often unconsciously applied by study staff for the definition
of confirmed FA. It also allows the reporting of FA as a con-
tinuous phenomenon with mild to severe forms.
We introduce a more differentiated interpretation of
DBPCFC outcomes based on verum and placebo days. From
comparing symptom severity and conclusion between two
challenge days, the allergy status is defined using a system of
10 different outcome levels, clustered into the three broad cate-
gories of NO food allergy, UNCERTAIN outcome and FOOD
Table 1
Type of eligibility A B C D
Questions 2/5: Have you/Has your child eaten [FOOD NAME]
recently (within the last 3 months) without symptoms?
Yes No No No
Question 1: Have you/Has your child ever had an illness or
trouble caused by eating [FOOD NAME] or even a diagnosis of food allergy?
* No No Yes
Sensitization * Negative
SPT/IgE
Positive or
missing
SPT/IgE
*
Eligible for oral food challenge No No Yes Yes
SPT, skin prick test; IgE, Immunoglobulin E. *information not needed for eligibility decision
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wileyonlinelibrary.com]
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ALLERGY. For example, FOOD ALLERGY can be diag-
nosed through three different approaches: clear signs and
symptoms on verum but none on placebo day, placebo signs
and symptoms but less severe compared to verum day, or clear
symptoms on verum day but no placebo challenge performed.
Distinguishing these levels can inform the researcher about dif-
ferences between projects and physicians and support estima-
tion of the degree of individual diagnostic certainty. We will be
able to validate the FA diagnosis internally as given by the
study physician against different approaches of defining FA
based on our detailed documentation of symptoms. Future
validation including assessment of interobserver reliability will
help identify areas for further improvement.
The overarching drawback of comparable and harmonized
FA diagnosis is that it will always rely on physician’s subjective
appraisal of patient’s/family’s report of observed signs and
symptoms of the patient. This cannot be overcome completely
but a common standard for reporting, documentation and
decision-making can minimize limitations of subjective inter-
pretations of blinded food challenges. Capturing subtle differ-
ences between physicians and settings might enable researchers
to report or potentially adjust for individual factors and sub-
jective perception. Beyond the generic SOPs we suggest here,
IT-supported decision-making for eligibility, stop criteria or
DBPCFC outcome judgment might be possible, but is compli-
cated by the multidimensionality of input information and
handling of rare exceptions, these are after all medical deci-
sions. As FA is a very complex and heterogeneous condition,
its investigation requires case definitions with a certain degree
of complexity. The methods presented here tried to balance
between ease of use and applicability on one side and capturing
as much information as possible on the other. Our approach
requires a thorough training and continued supervision to be
consistently applied in research and clinical care alike.
Measuring incidence and prevalence of FA in population-
based research is subject to certain restrictions such as
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Figure 3 Food allergy outcomes: NO food allergy, UNCERTAIN outcome and FOOD ALLERGY. Based on symptom severity on placebo and
verum day.
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dietary habits in a population (21). Only if an individual (or
parent) perceives a link between the ingestion of a specific
food item and occurring symptoms can these be reported in
the medical history. Without consuming a certain food, no
reactions will ever be reported despite a patient having devel-
oped dormant allergy. This can be improved by applying
allergic sensitization screening tests, but this approach will
miss allergies to food items that are not included in the test
battery and non-IgE-mediated reactions. To capture potential
reactions, which would not be detected through SPT/IgE-
screening, every person not currently consuming food items
in question would need to undergo a food challenge for all
these. Such cases are not detected with the proposed algo-
rithm. Therefore, prevalence can only be estimated validly
for IgE-mediated reactions. Furthermore, repeated assess-
ments in the same cohort are needed for incidence and more
informative prevalence estimates related to age at onset and
screening for latent allergies (22, 23).
Conclusions
We developed a comprehensive toolbox for improved docu-
mentation and decision-making using DBPCFC tests for FA
diagnosis, particularly in population-based epidemiological
and clinical research settings. The toolbox may also facilitate
decision-making in clinical routine care, but has not yet been
tested in this setting.
The presented methods have been applied in the EU-
funded iFAAM project as part of the school-age follow-up
of a multinational European birth cohort study. Case report
forms and SOPs are available as publicly accessible supple-
ments under Creative Commons licensing, and we encourage
their use in research and clinical settings as well as their
further evolution (Open Access online supplement). Trans-
lated, amended and updated versions are available online
(www.diagnosing-food-allergy.org). These harmonized tools
and methods foster comparability between study physicians
and centres as well as between different studies including
interventional studies, for example in the fields of
immunotherapy and primary/secondary prevention of FA.
Furthermore, they will help to evaluate regional prevalence
time trends, temporal courses of food allergies within the
same individuals, and support future meta-analyses of indi-
vidual participant data.
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